Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
730.00 GBX | -0.95% | -1.15% | +10.77% |
Nov. 18 | Tate & Lyle issues shares to complete purchase of CP Kelco | AN |
Nov. 15 | UK's Tate & Lyle Closes Purchase of CP Kelco | MT |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2.88B | 2.81B | 1.38B | 1.75B | 1.65B | |||||
Total Revenues | 2.88B | 2.81B | 1.38B | 1.75B | 1.65B | |||||
Cost of Goods Sold, Total | 1.63B | 1.66B | 696M | 876M | 796M | |||||
Gross Profit | 1.26B | 1.14B | 679M | 875M | 851M | |||||
Selling General & Admin Expenses, Total | 191M | 182M | 263M | 287M | 265M | |||||
Provision for Bad Debts | 5M | -2M | - | - | - | |||||
R&D Expenses | 34M | 43M | - | - | - | |||||
Depreciation & Amortization - (IS) | 137M | 142M | 56M | 59M | 58M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 35M | 33M | 24M | 36M | 36M | |||||
Other Operating Expenses | 530M | 412M | 173M | 270M | 261M | |||||
Other Operating Expenses, Total | 932M | 810M | 516M | 652M | 620M | |||||
Operating Income | 323M | 332M | 163M | 223M | 231M | |||||
Interest Expense, Total | -33M | -26M | -23M | -29M | -22M | |||||
Interest And Investment Income | 5M | 1M | 1M | 12M | 19M | |||||
Net Interest Expenses | -28M | -25M | -22M | -17M | -3M | |||||
Income (Loss) On Equity Invest. | 28M | 26M | - | -24M | 25M | |||||
Currency Exchange Gains (Loss) | -1M | - | -2M | -1M | - | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | 322M | 333M | 139M | 181M | 253M | |||||
Restructuring Charges | -24M | -20M | -1M | -5M | -21M | |||||
Merger & Related Restructuring Charges | - | - | - | - | -2M | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Asset Writedown | -2M | -8M | -17M | -1M | -1M | |||||
Insurance Settlements | - | 2M | - | - | - | |||||
Legal Settlements | - | -5M | - | -3M | - | |||||
Other Unusual Items | - | -19M | -79M | -20M | -3M | |||||
EBT, Incl. Unusual Items | 296M | 283M | 42M | 152M | 226M | |||||
Income Tax Expense | 51M | 30M | 16M | 25M | 47M | |||||
Earnings From Continuing Operations | 245M | 253M | 26M | 127M | 179M | |||||
Earnings Of Discontinued Operations | - | - | 210M | 63M | 9M | |||||
Net Income to Company | 245M | 253M | 236M | 190M | 188M | |||||
Net Income - (IS) | 245M | 253M | 236M | 190M | 188M | |||||
Net Income to Common Incl Extra Items | 245M | 253M | 236M | 190M | 188M | |||||
Net Income to Common Excl. Extra Items | 245M | 253M | 26M | 127M | 179M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.62 | 0.64 | 0.59 | 0.47 | 0.47 | |||||
Basic EPS - Continuing Operations | 0.62 | 0.64 | 0.07 | 0.31 | 0.45 | |||||
Basic Weighted Average Shares Outstanding | 398M | 398M | 399M | 404M | 397M | |||||
Net EPS - Diluted | 0.61 | 0.63 | 0.59 | 0.46 | 0.47 | |||||
Diluted EPS - Continuing Operations | 0.61 | 0.63 | 0.06 | 0.31 | 0.44 | |||||
Diluted Weighted Average Shares Outstanding | 403M | 402M | 403M | 411M | 404M | |||||
Normalized Basic EPS | 0.51 | 0.52 | 0.22 | 0.28 | 0.4 | |||||
Normalized Diluted EPS | 0.5 | 0.52 | 0.22 | 0.27 | 0.39 | |||||
Dividend Per Share | 0.35 | 0.36 | 0.22 | 0.18 | 0.19 | |||||
Payout Ratio | 55.92 | 54.15 | 61.02 | 38.42 | 40.43 | |||||
American Depositary Receipts Ratio (ADR) | 4 | 4 | 4 | 4 | 4 | |||||
Supplemental Items | ||||||||||
EBITDA | 464M | 478M | 250M | 296M | 303M | |||||
EBITA | 358M | 365M | 189M | 246M | 254M | |||||
EBIT | 323M | 332M | 163M | 223M | 231M | |||||
EBITDAR | 466M | 479M | - | - | - | |||||
Effective Tax Rate - (Ratio) | 17.23 | 10.6 | 38.1 | 16.45 | 20.8 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Current Foreign Taxes | - | - | - | - | - | |||||
Total Current Taxes | 41M | 48M | 36M | 45M | 71M | |||||
Total Deferred Taxes | 10M | -18M | -20M | -20M | -24M | |||||
Normalized Net Income | 201M | 208M | 86.88M | 113M | 158M | |||||
Interest on Long-Term Debt | 7M | 6M | 2M | 2M | 2M | |||||
Non-Cash Pension Expense | 2M | 7M | -8M | 5M | 3M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 34M | 43M | 41M | 46M | 44M | |||||
Net Rental Expense, Total | 2M | 1M | - | - | - | |||||
Imputed Operating Lease Interest Expense | 801K | 275K | - | - | - | |||||
Imputed Operating Lease Depreciation | 1.2M | 725K | - | - | - | |||||
Stock-Based Comp., Other (Total) | 14M | 8M | 12M | 20M | 13M | |||||
Total Stock-Based Compensation | 14M | 8M | 12M | 20M | 13M |